For the latest COVID information Click Here.
Updated June 2021
This information was written by the Australian Rheumatology Association to help you understand baricitinib. It includes important information about:
Please read it carefully and discuss it with your doctor.
Baricitinib (brand name Olumiant®) is a tablet that belongs to a class of medicines called Janus Kinase (JAK) inhibitors. JAK inhibitors work by blocking signals involved in inflammation. Blocking these signals in rheumatoid arthritis reduces pain, stiffness, swelling and damage in the joints.
Baricitinib is taken by mouth in tablet form. The tablet should be swallowed whole do not crush or break the tablet.
Baricitinib may be used alone or with other arthritis medicines including:
If you are taking probenecid tell your doctor as you may need a lower dose of baricitinib.
Baricitinib cannot be used with other biologic DMARDs or targeted synthetic DMARDS (such as tofacitinib).
You might experience side effects with your treatment. Tell your doctor if you notice side effects that you think are caused by this medicine. Many side effects disappear when baricitinib treatment is stopped.
Most common side effects
Less common or rare side effects
Use with other medicines
Use in pregnancy and when breastfeeding